Insider · CIK 0001839516
Dianne C. Whitfield
Files at TARS (Tarsus Pharmaceuticals, Inc.). First filing Dec 1, 2023, latest Mar 19, 2026.
In brief
Dianne C. Whitfield files SEC Form 4 as officer at TARS (Tarsus Pharmaceuticals, Inc.). Since Dec 1, 2023, Dianne C. Whitfield has reported 0 open-market buys worth $0 and 4 open-market sells worth $2.8M, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Dianne C. Whitfield has 0, so none is measured yet.
The newest scored trade: sold $839k of TARS on Mar 17, 2026, filed Mar 19, 2026, scored 63 (notable). In the last 12 months: 0 buys worth $0 and 3 sells worth $2.7M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Tarsus Pharmaceuticals, Inc. | $839k 12,274 shares | -26% | +80% from low-15% from high | |
| 38Weak | Tarsus Pharmaceuticals, Inc. | $1.3M 15,565 shares | -40% | +108% from low-2% from high | |
| 34Weak | Tarsus Pharmaceuticals, Inc. | $592k 7,397 shares | -16% | +102% from low-5% from high | |
| 24Weak | Tarsus Pharmaceuticals, Inc. | $136k 8,355 shares | -24% | +43% from low-33% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 4,174 0.01% of outstanding | $280k | Mar 19, 2026 | $1.8M |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 4,071 0.01% of outstanding | $280k | Mar 18, 2026 | $1.5M |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 4,029 0.01% of outstanding | $280k | Mar 17, 2026 | $1.3M |
| Jan 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 15,565 0.04% of outstanding | $1.3M | Jan 2, 2026 | $592k |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 7,397 0.02% of outstanding | $592k | Dec 16, 2025 | none |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 2,137 0.01% of outstanding | $107k | Mar 20, 2025 | $214k |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 2,259 0.01% of outstanding | $107k | Mar 19, 2025 | $107k |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 2,315 0.01% of outstanding | $107k | Mar 18, 2025 | none |
| Nov 30, 2023 | TARS Tarsus Pharmaceuticals, Inc. | 8,355 0.03% of outstanding | $136k | Nov 30, 2023 | none |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,029 | $69.42 | $280k | 43,273 | Mar 19, 2026 |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,071 | $68.71 | $280k | 39,202 | Mar 19, 2026 |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,174 | $67.00 | $280k | 35,028 | Mar 19, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +23,909 | - | - | 47,302 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,463 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,248 | $0.00 | $0 | 7,249 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,176 | $0.00 | $0 | 14,351 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Jan 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,715 | $80.09 | $458k | 33,243 | Jan 6, 2026 |
| Jan 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -8,122 | $80.71 | $656k | 25,121 | Jan 6, 2026 |
| Jan 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -835 | $81.90 | $68k | 24,286 | Jan 6, 2026 |
| Jan 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -893 | $82.93 | $74k | 23,393 | Jan 6, 2026 |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -7,397 | $80.10 | $592k | 38,958 | Dec 18, 2025 |
| Nov 29, 2023 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +23,920 | $0.00 | $0 | 35,139 | Dec 1, 2023 |
| Nov 30, 2023 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -8,355 | $16.31 | $136k | 26,784 | Dec 1, 2023 |
| Nov 29, 2023 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -23,920 | $0.00 | $0 | 0 | Dec 1, 2023 |
Questions about Dianne C. Whitfield
Answered from the filings on this page, as of the latest one.
Is Dianne C. Whitfield buying or selling?
In the last 12 months Dianne C. Whitfield reported 0 open-market buys worth $0 and 3 open-market sells worth $2.7M on SEC Form 4; the latest was sold $839k of TARS on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Dianne C. Whitfield's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dianne C. Whitfield has 0.
Where does Dianne C. Whitfield file Form 4?
Dianne C. Whitfield has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.) as Chief Human Resources Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.